February 19, 2025

Merck Serono S.A. v. TWi Pharmaceuticals, Inc.

Track this case

Case Number:

25-1463

Court:

Appellate - Federal Circuit

Nature of Suit:

Companies

Sectors & Industries:

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. January 22, 2026

    Merck Can't Get Fed. Circ. To Reconsider Axing MS Drug Patents

    The Federal Circuit on Thursday refused to reconsider decisions invalidating Merck KGaA patents on the blockbuster multiple sclerosis drug Mavenclad, turning aside the German drugmaker's claim that the court set an unjust new rule that means inventors' work can later be used against them.

2 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS